Markus Niggli
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Long-term outcomes with emicizumab in hemophilia A without inhibitors: results from the HAVEN 3 and 4 studies.
Journal: Research and practice in thrombosis and haemostasis
Published: February 01, 2024
Pharmacokinetics and coagulation biomarkers in children and adults with hemophilia A receiving emicizumab prophylaxis every 1, 2, or 4 weeks.
Journal: Research and practice in thrombosis and haemostasis
Published: April 18, 2023
Emicizumab dose up-titration in case of suboptimal bleeding control in people with haemophilia A.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: June 09, 2022
Effect of emicizumab prophylaxis on bone and joint health markers in people with haemophilia A without factor VIII inhibitors in the HAVEN 3 study.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: March 29, 2022
Low immunogenicity of emicizumab in persons with haemophilia A.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: June 11, 2021
The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: December 22, 2020
Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: September 03, 2020
Reply: RE: Reyes A, Révil C, Niggli M, et al. Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial. Curr Med Res Opin. 2019;35(12):2079-2087.
Journal: Current medical research and opinion
Published: March 18, 2020
Efficacy of emicizumab prophylaxis versus factor VIII prophylaxis for treatment of hemophilia A without inhibitors: network meta-analysis and sub-group analyses of the intra-patient comparison of the HAVEN 3 trial.
Journal: Current medical research and opinion
Published: July 30, 2019
Last Updated: 09/26/2026